NDAORALTABLET
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NEXTSTELLIS (drospirenone and estetrol) by Mayne Pharma is ovulation. First approved in 2021.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXTSTELLIS is an oral contraceptive combining drospirenone (a progestin) and estetrol (a novel estrogen) that prevents ovulation. It represents a new-generation hormonal contraceptive option for women seeking pregnancy prevention. The combination mechanism provides both ovulation suppression and endometrial control.
$0.078BPart D
Peak17.0 years to LOEProduct is at peak commercial maturity with stable Part D claims; brand team size likely established and focused on market penetration and retention.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEXTSTELLIS positions you within a stable, peak-lifecycle oral contraceptive brand with long patent protection and established market presence. Career growth depends on market share expansion and competitive positioning in the evolving contraceptive landscape, with roles spanning commercial, medical affairs, and market access.
Brand ManagerProduct Manager
Worked on NEXTSTELLIS at Mayne Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.